The urologist in the world of precision medicine
"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.
Optimization of Genetic Testing for mCRPC
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Sequencing Therapy for mCRPC
Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.
Role of PSMA PET Imaging in mCRPC
Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.
Patient Case #2: Choosing Optimal Therapy in mCRPC
Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.
The continuum of care in urologic oncology
"The explosion in the number of therapies in this particular disease segment, especially those that have been deemed BCG unresponsive, seems very reminiscent to that witnessed in the mCRPC space a decade ago," writes Raoul S. Concepcion, MD, FACS.
Treatment options for high-volume mCNPC
Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.
Role of conventional imaging vs PSMA-PET in mCNPC
A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.
Patient Case #1: Treatment Selection in mCNPC
Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.
Polling Questions: Advanced Prostate Cancer
Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.
The challenges of prostate cancer management
"The major shift for many urologists over the past 10 years has undoubtedly been the understanding of how to treat advanced prostate cancer," writes Raoul S. Concepcion, MD, FACS.
From Dr. Concepcion: Urology's history of embracing change
"As someone once told me, if you make a change in your golf swing and it is easy, more than likely you have not changed anything," writes Raoul S. Concepcion, MD, FACS.
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence
Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Sensitivity of Imaging Modalities to Biochemical Recurrence in Prostate Cancer
Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer.
Case 2: 64-Year-Old Man With Multifocal Prostate Cancer Post-IMRT
Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT.
Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer
Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection.
Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer
An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.
Case 1: 58-Year-Old Man 6 Months Post-Radical Prostatectomy
Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection.
Considerations for Initiating ADT After Biochemical Recurrence in Prostate Cancer
Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence.
Defining PSA Nadir After Definitive Therapy in Prostate Cancer
Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Best Practices for Monitoring After Definitive Therapy in Prostate Cancer
Dr Judd Moul and colleagues discuss best practices for monitoring patients with prostate cancer after definitive therapy.
Rate of BCR in Prostate Cancer
Dr Raoul Concepcion leads a panel of experts in prostate cancer in setting the stage for case-based discussions of biochemical recurrence.
2 Clarke Drive Cranbury, NJ 08512